Skip to contentT
Travere Therapeutics, Inc.
T
TVTXTravere Therapeutics, Inc. Q2 2021 · 10-Q
Revenue$54.62M$54.62M+12.8% vs Q2 2020 Net Income-$39.01M-$39.01MN/M vs Q2 2020 EPS Diluted-$0.64-$0.64N/M vs Q2 2020 Operating Income-$35,315,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Travere Therapeutics, Inc. · CIK 1438533 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$6,393,000N/M Margins · derivedOperating margin-64.7%−16.9 pt vs Q2 2020
Net margin-71.4%−17.6 pt vs Q2 2020
ended Jun 30, 2021 · filed Jul 29, 2021 · 29 d after period end